Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06078696 · ClinicalTrials.gov registry record · Phase 1
Siplizumab for Sickle Cell Disease Transplant
A Phase 1 study, sponsored by Columbia University.
- Terminated
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT06078696 is a Phase 1 study that was terminated before completion, run by Columbia University. The registered enrollment target is 1 participants.
The verdict
NCT06078696, a Phase 1 study, was terminated before completion, sponsored by Columbia University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
The purpose of this study is to find out whether siplizumab is safe and effective for patients with SCD undergoing an allogeneic transplant and to prevent development of Graft versus Host Disease (GVHD) and graft failure. The main goals of this study are : * To determine if acute GVHD occurs and how severe the acute GVHD is in subjects receiving the study drug * To determine if graft failure occurs in subjects receiving the study drugs In this study, participants will receive 5 infusions of the study drug, siplizumab, while getting a stem cell transplant for SCD. Before siplizumab infusion, participants will be given medications to reduce the risks of allergic reaction to the drug.
Interventions
- PROCEDURE Exchange Transfusion
- DRUG Siplizumab
- DRUG Cyclophosphamide 50mg
- PROCEDURE Stem Cell Infusion
- PROCEDURE Total Body Irradiation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2023-09-28 |
| Est. Completion | 2025-12-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06078696
The ClinicalTrials.gov registry entry for NCT06078696 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Exchange Transfusion is the first listed.
NCT06078696 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06078696 about?
NCT06078696 is a clinical study titled "Siplizumab for Sickle Cell Disease Transplant". The purpose of this study is to find out whether siplizumab is safe and effective for patients with SCD undergoing an allogeneic transplant and to prevent development of Graft versus Host Disease (GVHD) and graft failure. The main goals of this study are : * To determine if acute GVHD occurs and ho...
What is the current status of trial NCT06078696?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2023-09-28. Estimated completion is 2025-12-11.
What interventions are being tested in trial NCT06078696?
The interventions under investigation include: Exchange Transfusion (PROCEDURE), Siplizumab (DRUG), Cyclophosphamide 50mg (DRUG), Stem Cell Infusion (PROCEDURE), Total Body Irradiation (PROCEDURE).
Who is sponsoring clinical trial NCT06078696?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.